Top Chicago, IL Health Tech Companies With Best Stability & Growth (357)

Investor Backing & Capital Strength: New growth capital was secured via a $65M growth investment led by existing investors, signaling continued access to funding to support scaling. The investment is repeatedly tied to accelerating adoption and expansion plans into 2026.

Strong Revenue Growth: A milestone of $100M in Contracted ARR (CARR) by the end of 2025 is cited as evidence of expanding contracted recurring revenue. The data is positioned as a major step-up in commercial scale for the artera.io business.

Market Expansion: Customer footprint and usage claims indicate expansion from earlier scale figures to “1,000+ healthcare organizations,” with materially higher annual communication volumes and patients reached. New logo mentions such as adding FQHCs and ongoing segment wins are presented as continued go-to-market traction.

Market Expansion: Expansion is evident through entry into adjacent regulated education markets, including the launch of Aceable Insurance in March 2025 with plans to add more states and the rollout of Aceable Mortgage via rebranding.

Product Line Growth: Product scope is broadening beyond legacy driver’s ed into insurance, mortgage, and expanded professional licensing catalogs, supported by explicit new vertical launches and rebrands.

Investor Backing & Capital Strength: Capital strength is supported by the previously announced $50M growth investment (Dec 2020), which provides a funding foundation for continued expansion even without newly reported 2025–2026 rounds.

Investor Backing & Capital Strength: Fresh external capital is shown by multiple trackers reporting a roughly $26.3M round dated January 3, 2025, bringing total disclosed funding to about $76M. Continued fundraising at this stage suggests runway to support scaling initiatives in product and go-to-market.

Product Line Growth: Product positioning indicates a move from point solutions toward a broader platform, with Truzo described as an end-to-end drug discount management platform alongside earlier offerings like 340B Pay. Ongoing enhancement messaging (e.g., refreshes to Commercial Discount Monitoring) is consistent with continued expansion of the product suite.

Strong Market Position & Advantage: Concrete manufacturer-side uptake is evidenced by industry notes that Alkermes moved contract-pharmacy claims to Truzo effective December 1, 2025. Trade coverage frequently places Kalderos among the leading vendors in manufacturer-focused duplicate-discount detection workflows, indicating sustained competitive relevance in its niche.

Innovation-Driven Growth: Product releases continued through 2025 alongside implemented AI workflows and the launch of “Ask ALIS,” indicating sustained investment in new capabilities. The “ALIS 500” benchmarking program also expands the product surface into operational and clinical analytics using large-scale community data.

Strategic Partnerships: Client and vendor partnerships expanded in 2025, and the company highlighted deeper ecosystem activity through integrations and partner announcements. Processing large payment volumes and reporting growth in vendor partnerships suggest increasing embeddedness in operators’ workflows and adjacent vendor stacks.

Strong Hiring & Retention: Team growth was reported alongside broader scaling activities such as hosting the first user conference and expanding partnerships. External directories and LinkedIn headcount bands also align with an organization adding capacity to support expansion, even if exact figures are not company-verified.

Market Expansion: Footprint expansion is evidenced by new office capacity (e.g., a 50,000 sq ft Hyderabad office sized for several hundred employees) and stated presence across 35+ offices worldwide, indicating geographic scaling. Capability-center strategy and India-focused delivery growth are repeatedly cited as a central expansion vector into 2025–2026.

Strong Hiring & Retention: Hiring plans reference adding thousands of roles globally with a large share in India, aligning with the reported rise in overall employee counts over time. Internal promotion volume is also highlighted as an indicator of ongoing organizational scaling and talent pipeline movement.

Innovation-Driven Growth: Acquisitions and investments are described as expanding AI, analytics, and Salesforce-enabled delivery (e.g., Torrent Consulting and Digital Additive), supporting a shift toward tech-enabled consulting and platforms. External recognitions in AI/analytics and life sciences service categories are cited as reinforcing momentum in these growth areas.

Strategic Partnerships: Strategic alignment is strengthened by the March 27, 2025 acquisition by Kardigan to integrate Prolaio’s cardiovascular data/algorithms with a drug-development platform, which typically expands resources and distribution leverage. Post-acquisition messaging also frames Prolaio as a central technology unit within Kardigan’s broader “cardiac intelligence” strategy.

Strong Hiring & Retention: Hiring activity appears sustained, with roughly a dozen-plus open roles and senior leadership searches (e.g., CIO, CDAO, VP Supply Chain) cited across company profiles and job boards. Reported headcount ranges (e.g., ~60+ employees) and notes about dozens of hires during 2025 indicate ongoing team buildout.

Innovation-Driven Growth: Operational maturity is signaled by ISO 13485 and MDSAP certifications and by continued expansion of regulated capabilities, including references to multiple FDA-cleared algorithms and large-scale data generation. Study activity such as the national, all-remote OCORO Heart Study (targeting up to 5,000 participants) indicates continued investment in data and program expansion.

Strong Revenue Growth: Revenue is described as rising rapidly across multiple quarters, with particularly strong expansion in Diagnostics and continued growth in Data & Applications. Guidance for the next year indicates continued scaling from an already larger revenue base.

Customer Loyalty & Retention: Contracted commercial momentum is supported by a large remaining contract value balance and net revenue retention that indicates expanding spend from existing customers. These indicators suggest forward visibility and repeatable demand rather than one-off transactions.

Investor Backing & Capital Strength: Cash and marketable securities are described as substantial, providing financial flexibility to keep investing through an expansion phase. This liquidity is positioned as a buffer that can support continued product build-out and commercialization.

Investor Backing & Capital Strength: A definitive agreement for Advent International to acquire PatientPoint is framed as providing capital and an explicit mandate to accelerate network expansion and product innovation, signaling strong sponsor conviction.

Strong Market Position & Advantage: PatientPoint is repeatedly positioned as operating the nation’s largest digital point-of-care network, with large reported scale in physician-office locations, devices, and provider relationships that supports category leadership.

Market Expansion: Growth signals include the 2021 combination with Outcome Health and ongoing network/footprint expansion claims across tens of thousands of locations, alongside continued deal and partnership activity aimed at extending reach.

Market Expansion: Expansion is framed through the August 2023 combination with Syntellis, which broadened reach beyond healthcare into higher education and financial services and increased the addressable market. The company also highlights a larger stated footprint of “more than 2,300 organizations” using StrataJazz and Axiom, signaling broadened penetration.

Strong Market Position & Advantage: Category leadership is reinforced through repeated Best in KLAS recognition (including references to an 18-year streak for Business Decision Support and continued wins in 2024–2025). Frequent citation of Strata’s benchmarking products and large comparative datasets also suggests strong embeddedness and defensibility in provider finance workflows.

Innovation-Driven Growth: Ongoing investment is emphasized through AI-focused product development (e.g., StrataSignal and new capabilities showcased at user summits) and continued module launches like Position Control. A data-platform collaboration with Snowflake is positioned as scaling analytics capacity to meet rapidly increasing customer data requirements.

Strong Revenue Growth: Annual revenue shows an upward trend across 2023–2024, and early-2025 reporting highlights a strong year-over-year increase alongside higher submission volume. Management also set an explicit near-term revenue growth target supported by a shift toward higher-margin services.

Strategic Partnerships: A large co-location partnership targets a broad physical footprint by end-2026, which can expand access to Medicare-eligible consumers. This is complemented by strategic moves aimed at dual-eligible populations and ecosystem adjacency.

Diversified Revenue Streams: Expansion beyond core Medicare brokerage is described through new subscription offerings and additional service lines such as telehealth/care coordination and product suite extensions. The acquisition of a home health agency also supports a broader, more integrated revenue mix over time.